Little Green Pharma (ASX:LGP) share price lifts as bosses reflect on a big year

The Little Green Pharma share price is in the green today.

| More on:
heavy lifting, lifting index, carrying weight, boy lifting dumbbell above his head

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Little Green Pharma Ltd (ASX: LGP) share price is gaining today as its leaders comment on the company's "laser focus" towards rapid growth.

The medicinal cannabis producer and distributor released its annual report for financial year 2021 today. Within it, the company's bosses looked back on the year that brought its maiden profit and first expansion into Europe.

At the time of writing, the Little Green Pharma share price is 69.5 cents, 1.46% higher than its previous close.

Let's take a closer look at what Little Green Pharma's leaders had to say about its financial year 2021 and its future.

Financial year 2021 for Little Green Pharma

The Little Green Pharma share price is in the green today amid the release of its annual report.

The company's managing director and chair both provided comments within the report, each detailing a successful financial year.

Over financial year 2021, Little Green Pharma acquired a medicinal cannabis cultivation and manufacturing facility in Denmark and grew its relationship with its German distribution partner, Demecan.

It has also positioned itself to break into the French, Danish, and Polish markets.

Additionally, Solomon noted the company's products saw record growth in demand in financial year 2021, with 10,600 new patients.

Little Green Pharma's managing director, Fleta Solomon, said:

To know we could batten down the hatches, ride out the pandemic, and grow organically was a testament to our strong business model and team.

Little Green Pharma's chair, Michael Lynch-Bell, noted the acquisition of the Denmark facility represented a "step change" for the company. Particularly, as the placement it underwent to purchase the facility received strong institutional support.

The Little Green Pharma share price gained 10% on news of the acquisition and placement.

Now, the company is working on an observational study conducted by the University of Sydney. The findings of the study are expected to be peer-reviewed and published in 2022.

Additionally, a clinical investigation into its LGP Classic 10:10 medicinal cannabis oil has found it can safely treat chronic refractory pain. Little Green Pharma is now progressing another clinical trial into the efficacy of medicinal cannabis in the treatment of symptoms of fibromyalgia.

Finally, the company's ARISE project is moving through the first of 3 phases.

Little Green Pharma share price snapshot

Today's boost included, the Little Green Pharma share price has gained 24% since the start of 2021. It is also 148% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »